Flexion Therapeutics (NASDAQ: FLXN) is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis.

Zilretta™ (FX006), Flexion’s lead investigational drug candidate, is being investigated as the first intra-articular, extended-release treatment for patients with knee OA pain and was developed with the goal of enhancing the clinical effect of intra-articular corticosteroid treatment.

In December 2016, we submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for Zilretta based on previously reported positive results from a pivotal Phase 3 clinical trial.

Flexion is based in Burlington, Massachusetts.